泰嘉股份(002843) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 443,904,192.10, a decrease of 0.59% compared to CNY 446,544,550.80 in the same period last year[5] - Net profit attributable to shareholders was CNY 32,011,715.33, down 12.95% from CNY 36,774,518.42 year-on-year[5] - Basic and diluted earnings per share were both CNY 0.13, representing a decrease of 23.53% from CNY 0.17 in the same quarter last year[5] - Operating profit for Q1 2024 was CNY 27.08 million, down 37.5% from CNY 43.29 million in the same period last year[19] - The company reported a comprehensive income of CNY 26.87 million for Q1 2024, compared to CNY 32.03 million in Q1 2023, indicating a decline of 16.1%[19] Cash Flow and Liquidity - Operating cash flow net amount reached CNY 50,534,467.20, a significant increase of 1,662.72% compared to a negative cash flow of CNY -3,233,753.98 in the previous year[5] - The net cash flow from operating activities for Q1 2024 was ¥50,534,467.20, a significant improvement compared to a net outflow of ¥3,233,753.98 in the same period last year[20] - Total cash inflow from operating activities was ¥505,867,219.16, while cash outflow was ¥455,332,751.96, resulting in a positive net cash flow[20] - The company reported a decrease in cash and cash equivalents from 712,542,342.97 CNY at the beginning of the period to 382,024,439.99 CNY at the end[15] - The ending balance of cash and cash equivalents was ¥261,589,870.02, a decrease from ¥675,697,944.57 at the beginning of the period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,573,523,402.00, a decrease of 4.74% from CNY 2,701,559,883.83 at the end of the previous year[5] - Total liabilities decreased to CNY 1.16 billion in Q1 2024 from CNY 1.19 billion in Q1 2023, a reduction of 2.68%[17] - The company's equity attributable to shareholders was CNY 1,413,944,365.71, down 2.40% from CNY 1,448,704,003.67 at the end of the last year[5] - Deferred income tax assets increased to CNY 159.13 million in Q1 2024 from CNY 151.08 million in Q1 2023, reflecting potential future tax benefits[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,853[10] - The largest shareholder, Changsha Zhengyuan Enterprise Management Co., Ltd., holds 22.90% of shares, totaling 57,897,350 shares, with 11,970,000 shares pledged[10] - The total number of preferred shareholders at the end of the reporting period is 0[13] Investment and Expenses - Research and development expenses increased to CNY 17.03 million in Q1 2024, up from CNY 15.49 million in Q1 2023, indicating a focus on innovation[18] - Investment activities resulted in a cash outflow of CNY -320,730,148.09, a decrease of 2,311.23% compared to CNY 14,504,606.74 in the previous year[8] - Payments for the purchase of goods and services were ¥274,348,841.68, a decrease from ¥397,566,717.49 year-over-year, indicating a reduction of approximately 30.9%[20] Other Financial Metrics - The company reported a significant increase in contract liabilities by 72.69%, reaching CNY 4,642,859.50, compared to CNY 2,688,501.59 in the previous year[8] - Other income decreased by 57.25% to CNY 3,064,003.85, primarily due to a reduction in government subsidies received[8] - The company experienced a 99.97% decrease in minority interests, amounting to CNY 15,036.98, due to the acquisition of remaining minority shares in Platinum Electronics[8] - Accounts receivable increased from 388,311,202.33 CNY to 432,501,388.00 CNY, indicating a growth of approximately 11.4%[15] - The total current assets decreased from 1,613,718,893.00 CNY to 1,464,460,030.26 CNY, a decline of about 9.2%[15] Market and Future Outlook - The company has not disclosed any significant new product developments or technological advancements in the current report[14] - There is no indication of market expansion or mergers and acquisitions in the current financial report[14] - The company has not provided specific future outlook or performance guidance in the current report[14]